Only 1 (3%) patient, a CAR-T therapy recipient for diffuse large B-cell lymphoma, treated with bamlanivimab for mild COVID-19 progressed to severe disease requiring ICU care. To the Editor - We read with interest the article by Ganesh et al regarding monoclonal antibody (mAb) therapy for coronavirus disease 2019 (COVID-19) in high-risk patients [[1]]. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19. 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19. [Extracted from the article]